BSE Live
Mar 25, 16:01Prev. Close
1219.30
Open Price
1228.45
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 25, 15:59Prev. Close
1219.40
Open Price
1222.70
Bid Price (Qty.)
1244.40 (105)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Cipla (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 9,831.88 | 9,174.96 | 8,134.56 | 6,931.92 | 6,193.82 | |
| Less: Excise/Sevice Tax/Other Levies | 92.94 | 99.12 | 92.16 | 97.23 | 67.64 | |
| Revenue From Operations [Net] | 9,738.94 | 9,075.84 | 8,042.40 | 6,834.69 | 6,126.18 | |
| Total Operating Revenues | 10,131.78 | 9,380.29 | 8,202.42 | 6,977.50 | 6,331.09 | |
| Other Income | 147.91 | 280.28 | 229.13 | 148.30 | 91.64 | |
| Total Revenue | 10,279.69 | 9,660.57 | 8,431.55 | 7,125.80 | 6,422.73 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 3,426.74 | 3,145.34 | 2,646.83 | 2,300.85 | 2,356.12 | |
| Purchase Of Stock-In Trade | 903.41 | 773.40 | 706.89 | 555.55 | 671.13 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -349.05 | -158.12 | -290.75 | 11.24 | -138.71 | |
| Employee Benefit Expenses | 1,505.58 | 1,284.75 | 969.28 | 728.21 | 540.33 | |
| Finance Costs | 136.05 | 127.86 | 33.38 | 26.63 | 12.92 | |
| Depreciation And Amortisation Expenses | 433.20 | 323.61 | 303.03 | 282.07 | 248.03 | |
| Other Expenses | 2,683.79 | 2,345.39 | 2,051.03 | 1,799.79 | 1,581.52 | |
| Total Expenses | 8,739.72 | 7,842.23 | 6,419.69 | 5,704.34 | 5,271.34 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1,539.97 | 1,818.34 | 2,011.86 | 1,421.46 | 1,151.39 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 1,539.97 | 1,818.34 | 2,011.86 | 1,421.46 | 1,151.39 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 318.78 | 400.00 | 386.00 | 277.50 | 227.70 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | -70.00 | 0.00 | 70.00 | |
| Deferred Tax | 40.10 | 30.00 | 48.75 | 20.00 | 33.30 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 358.88 | 430.00 | 504.75 | 297.50 | 191.00 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 1,181.09 | 1,388.34 | 1,507.11 | 1,123.96 | 960.39 | |
| Profit/Loss From Continuing Operations | 1,181.09 | 1,388.34 | 1,507.11 | 1,123.96 | 960.39 | |
| Profit/Loss For The Period | 1,181.09 | 1,388.34 | 1,507.11 | 1,123.96 | 960.39 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 14.71 | 17.29 | 18.77 | 14.00 | 11.96 | |
| Diluted EPS (Rs.) | 14.66 | 17.29 | 18.77 | 14.00 | 11.96 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 1,523.87 | 1,745.19 | 1,097.17 | 925.53 | 1,005.14 | |
| Indigenous Raw Materials | 2,004.38 | 1,537.46 | 1,665.58 | 1,466.77 | 1,444.81 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 160.59 | 160.58 | 160.58 | 160.58 | 224.81 | |
| Tax On Dividend | 32.69 | 27.29 | 27.29 | 26.05 | 36.72 | |
| Equity Dividend Rate (%) | 100.00 | 100.00 | 100.00 | 100.00 | 140.00 |
19.03.2026
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
23.02.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
25.03.2026
25.03.2026
25.03.2026
24.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth